SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-12-458846
Filing Date
2012-11-08
Accepted
2012-11-08 07:02:05
Documents
11
Period of Report
2012-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d409160d10q.htm 10-Q 623327
2 EXHIBIT 10.49 d409160dex1049.htm EX-10.49 31537
3 EXHIBIT 31.1 d409160dex311.htm EX-31.1 9603
4 EXHIBIT 31.2 d409160dex312.htm EX-31.2 9543
5 EXHIBIT 32.1 d409160dex321.htm EX-32.1 5236
  Complete submission text file 0001193125-12-458846.txt   5410352

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT vnda-20120930.xml EX-101.INS 802212
7 XBRL TAXONOMY EXTENSION SCHEMA vnda-20120930.xsd EX-101.SCH 51613
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20120930_cal.xml EX-101.CAL 66137
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20120930_def.xml EX-101.DEF 122416
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20120930_lab.xml EX-101.LAB 379801
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20120930_pre.xml EX-101.PRE 277127
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 121188391
SIC: 2834 Pharmaceutical Preparations